21.7.2015   

EN

Official Journal of the European Union

C 238/8

1.

On 10 July 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings The Goldman Sachs Group, Inc. (‘Goldman Sachs’, United States) and Altor Fund IV (‘Altor’, Sweden) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of the undertaking Hamlet Protein A/S (‘Hamlet’, Denmark) by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

—   for Goldman Sachs: global investment banking, securities and investment management,

—   for Altor: private equity investment firm focusing on the mid-market segment of the Nordic region,

—   for Hamlet: development, production and sale of soya proteins for animal feed.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7682 — Goldman Sachs/Altor/Hamlet, to the following address: